Literature DB >> 1827210

Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein.

S Khusmith1, Y Charoenvit, S Kumar, M Sedegah, R L Beaudoin, S L Hoffman.   

Abstract

The circumsporozoite (CS) protein has been the target for development of malaria sporozoite vaccines for a decade. However, immunization with subunit vaccines based on the CS protein has never given the complete protection found after immunization with irradiated sporozoites. BALB/c mice immunized with irradiated Plasmodium yoelii sporozoites produced antibodies and cytotoxic T cells against a 140-kilodalton protein, sporozoite surface protein 2 (SSP2). Mice immunized with P815 cells that had been transfected with either SSP2 or CS genes were partially protected, and those immunized with a mixture of SSP2 and CS transfectants were completely protected against malaria. These studies emphasize the importance of vaccine delivery systems in achieving protection and define a multi-antigen sporozoite vaccine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1827210     DOI: 10.1126/science.1827210

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  58 in total

1.  Conservation of Babesia bovis small heat shock protein (Hsp20) among strains and definition of T helper cell epitopes recognized by cattle with diverse major histocompatibility complex class II haplotypes.

Authors:  Junzo Norimine; Juan Mosqueda; Guy H Palmer; Harris A Lewin; Wendy C Brown
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

Review 2.  Recombinant avirulent salmonellae as oral vaccine carriers.

Authors:  F Schödel
Journal:  Infection       Date:  1992 Jan-Feb       Impact factor: 3.553

3.  Naturally acquired IgG antibodies against the C-terminal part of Plasmodium falciparum sporozoite threonine-asparagine-rich protein in a low endemic area.

Authors:  Chittakun Suwancharoen; Chaturong Putaporntip; Thanaporn Rungruang; Somchai Jongwutiwes
Journal:  Parasitol Res       Date:  2011-02-01       Impact factor: 2.289

4.  A new antigen of Cryptosporidium parvum micronemes possessing epitopes cross-reactive with macrogamete granules.

Authors:  A Bonnin; J F Dubremetz; P Camerlynck
Journal:  Parasitol Res       Date:  1993       Impact factor: 2.289

Review 5.  The development of a multivalent DNA vaccine for malaria.

Authors:  R C Hedstrom; D L Doolan; R Wang; M J Gardner; A Kumar; M Sedegah; R A Gramzinski; J B Sacci; Y Charoenvit; W R Weiss; M Margalith; J A Norman; P Hobart; S L Hoffman
Journal:  Springer Semin Immunopathol       Date:  1997

6.  Immunization of cattle with recombinant Babesia bovis merozoite surface antigen-1.

Authors:  S A Hines; G H Palmer; D P Jasmer; W L Goff; T F McElwain
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

7.  Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2.

Authors:  B Wizel; R A Houghten; K C Parker; J E Coligan; P Church; D M Gordon; W R Ballou; S L Hoffman
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

8.  A conserved peptide sequence of the Plasmodium falciparum circumsporozoite protein and antipeptide antibodies inhibit Plasmodium berghei sporozoite invasion of Hep-G2 cells and protect immunized mice against P. berghei sporozoite challenge.

Authors:  S Chatterjee; M Wery; P Sharma; V S Chauhan
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

Review 9.  Murine infection models for vaccine development: the malaria example.

Authors:  Kai Matuschewski
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

10.  Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria.

Authors:  S Li; M Rodrigues; D Rodriguez; J R Rodriguez; M Esteban; P Palese; R S Nussenzweig; F Zavala
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.